<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20231124011111&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20231124011111&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Fri, 24 Nov 2023 06:11:12 +0000</lastbuilddate>
<pubDate>Thu, 23 Nov 2023 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37995658/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231124011111&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Nov 22;186(24):5428-5432. doi: 10.1016/j.cell.2023.10.008.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37995658/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231124011111&v=2.17.9.post6+86293ac">37995658</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.10.008>10.1016/j.cell.2023.10.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37995658</guid>
<pubDate>Thu, 23 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Man Lung Yeung</dc:creator>
<dc:creator>Jade Lee Lee Teng</dc:creator>
<dc:creator>Lilong Jia</dc:creator>
<dc:creator>Chaoyu Zhang</dc:creator>
<dc:creator>Chengxi Huang</dc:creator>
<dc:creator>Jian-Piao Cai</dc:creator>
<dc:creator>Runhong Zhou</dc:creator>
<dc:creator>Kwok-Hung Chan</dc:creator>
<dc:creator>Hanjun Zhao</dc:creator>
<dc:creator>Lin Zhu</dc:creator>
<dc:creator>Kam-Leung Siu</dc:creator>
<dc:creator>Sin-Yee Fung</dc:creator>
<dc:creator>Susan Yung</dc:creator>
<dc:creator>Tak Mao Chan</dc:creator>
<dc:creator>Kelvin Kai-Wang To</dc:creator>
<dc:creator>Jasper Fuk-Woo Chan</dc:creator>
<dc:creator>Zongwei Cai</dc:creator>
<dc:creator>Susanna Kar Pui Lau</dc:creator>
<dc:creator>Zhiwei Chen</dc:creator>
<dc:creator>Dong-Yan Jin</dc:creator>
<dc:creator>Patrick Chiu Yat Woo</dc:creator>
<dc:creator>Kwok-Yung Yuen</dc:creator>
<dc:date>2023-11-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system</dc:title>
<dc:identifier>pmid:37995658</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.10.008</dc:identifier>
</item>
<item>
<title>S. aureus drives itch and scratch-induced skin damage through a V8 protease-PAR1 axis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37995657/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231124011111&amp;v=2.17.9.post6+86293ac
      <description>Itch is an unpleasant sensation that evokes a desire to scratch. The skin barrier is constantly exposed to microbes and their products. However, the role of microbes in itch generation is unknown. Here, we show that Staphylococcus aureus, a bacterial pathogen associated with itchy skin diseases, directly activates pruriceptor sensory neurons to drive itch. Epicutaneous S. aureus exposure causes robust itch and scratch-induced damage. By testing multiple isogenic bacterial mutants for virulence...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Nov 22;186(24):5375-5393.e25. doi: 10.1016/j.cell.2023.10.019.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Itch is an unpleasant sensation that evokes a desire to scratch. The skin barrier is constantly exposed to microbes and their products. However, the role of microbes in itch generation is unknown. Here, we show that Staphylococcus aureus, a bacterial pathogen associated with itchy skin diseases, directly activates pruriceptor sensory neurons to drive itch. Epicutaneous S. aureus exposure causes robust itch and scratch-induced damage. By testing multiple isogenic bacterial mutants for virulence factors, we identify the S. aureus serine protease V8 as a critical mediator in evoking spontaneous itch and alloknesis. V8 cleaves proteinase-activated receptor 1 (PAR1) on mouse and human sensory neurons. Targeting PAR1 through genetic deficiency, small interfering RNA (siRNA) knockdown, or pharmacological blockade decreases itch and skin damage caused by V8 and S. aureus exposure. Thus, we identify a mechanism of action for a pruritogenic bacterial factor and demonstrate the potential of inhibiting V8-PAR1 signaling to treat itch.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37995657/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231124011111&v=2.17.9.post6+86293ac">37995657</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.10.019>10.1016/j.cell.2023.10.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37995657</guid>
<pubDate>Thu, 23 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Liwen Deng</dc:creator>
<dc:creator>Flavia Costa</dc:creator>
<dc:creator>Kimbria J Blake</dc:creator>
<dc:creator>Samantha Choi</dc:creator>
<dc:creator>Arundhasa Chandrabalan</dc:creator>
<dc:creator>Muhammad Saad Yousuf</dc:creator>
<dc:creator>Stephanie Shiers</dc:creator>
<dc:creator>Daniel Dubreuil</dc:creator>
<dc:creator>Daniela Vega-Mendoza</dc:creator>
<dc:creator>Corinne Rolland</dc:creator>
<dc:creator>Celine Deraison</dc:creator>
<dc:creator>Tiphaine Voisin</dc:creator>
<dc:creator>Michelle D Bagood</dc:creator>
<dc:creator>Lucia Wesemann</dc:creator>
<dc:creator>Abigail M Frey</dc:creator>
<dc:creator>Joseph S Palumbo</dc:creator>
<dc:creator>Brian J Wainger</dc:creator>
<dc:creator>Richard L Gallo</dc:creator>
<dc:creator>Juan-Manuel Leyva-Castillo</dc:creator>
<dc:creator>Nathalie Vergnolle</dc:creator>
<dc:creator>Theodore J Price</dc:creator>
<dc:creator>Rithwik Ramachandran</dc:creator>
<dc:creator>Alexander R Horswill</dc:creator>
<dc:creator>Isaac M Chiu</dc:creator>
<dc:date>2023-11-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>S. aureus drives itch and scratch-induced skin damage through a V8 protease-PAR1 axis</dc:title>
<dc:identifier>pmid:37995657</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.10.019</dc:identifier>
</item>
<item>
<title>Lineage-specific 3D genome organization is assembled at multiple scales by IKAROS</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37995656/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231124011111&amp;v=2.17.9.post6+86293ac
      <description>A generic level of chromatin organization generated by the interplay between cohesin and CTCF suffices to limit promiscuous interactions between regulatory elements, but a lineage-specific chromatin assembly that supersedes these constraints is required to configure the genome to guide gene expression changes that drive faithful lineage progression. Loss-of-function approaches in B cell precursors show that IKAROS assembles interactions across megabase distances in preparation for lymphoid...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Nov 22;186(24):5269-5289.e22. doi: 10.1016/j.cell.2023.10.023.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">A generic level of chromatin organization generated by the interplay between cohesin and CTCF suffices to limit promiscuous interactions between regulatory elements, but a lineage-specific chromatin assembly that supersedes these constraints is required to configure the genome to guide gene expression changes that drive faithful lineage progression. Loss-of-function approaches in B cell precursors show that IKAROS assembles interactions across megabase distances in preparation for lymphoid development. Interactions emanating from IKAROS-bound enhancers override CTCF-imposed boundaries to assemble lineage-specific regulatory units built on a backbone of smaller invariant topological domains. Gain of function in epithelial cells confirms IKAROS' ability to reconfigure chromatin architecture at multiple scales. Although the compaction of the Igκ locus required for genome editing represents a function of IKAROS unique to lymphocytes, the more general function to preconfigure the genome to support lineage-specific gene expression and suppress activation of extra-lineage genes provides a paradigm for lineage restriction.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37995656/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231124011111&v=2.17.9.post6+86293ac">37995656</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.10.023>10.1016/j.cell.2023.10.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37995656</guid>
<pubDate>Thu, 23 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Yeguang Hu</dc:creator>
<dc:creator>Daniela Salgado Figueroa</dc:creator>
<dc:creator>Zhihong Zhang</dc:creator>
<dc:creator>Margaret Veselits</dc:creator>
<dc:creator>Sourya Bhattacharyya</dc:creator>
<dc:creator>Mariko Kashiwagi</dc:creator>
<dc:creator>Marcus R Clark</dc:creator>
<dc:creator>Bruce A Morgan</dc:creator>
<dc:creator>Ferhat Ay</dc:creator>
<dc:creator>Katia Georgopoulos</dc:creator>
<dc:date>2023-11-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Lineage-specific 3D genome organization is assembled at multiple scales by IKAROS</dc:title>
<dc:identifier>pmid:37995656</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.10.023</dc:identifier>
</item>
<item>
<title>Molecular basis of opioid receptor signaling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37995655/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231124011111&amp;v=2.17.9.post6+86293ac
      <description>Opioids are used for pain management despite the side effects that contribute to the opioid crisis. The pursuit of non-addictive opioid analgesics remains unattained due to the unresolved intricacies of opioid actions, receptor signaling cascades, and neuronal plasticity. Advancements in structural, molecular, and computational tools illuminate the dynamic interplay between opioids and opioid receptors, as well as the molecular determinants of signaling pathways, which are potentially...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Nov 22;186(24):5203-5219. doi: 10.1016/j.cell.2023.10.029.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Opioids are used for pain management despite the side effects that contribute to the opioid crisis. The pursuit of non-addictive opioid analgesics remains unattained due to the unresolved intricacies of opioid actions, receptor signaling cascades, and neuronal plasticity. Advancements in structural, molecular, and computational tools illuminate the dynamic interplay between opioids and opioid receptors, as well as the molecular determinants of signaling pathways, which are potentially interlinked with pharmacological responses. Here, we review the molecular basis of opioid receptor signaling with a focus on the structures of opioid receptors bound to endogenous peptides or pharmacological agents. These insights unveil specific interactions that dictate ligand selectivity and likely their distinctive pharmacological profiles. Biochemical analysis further unveils molecular features governing opioid receptor signaling. Simultaneously, the synergy between computational biology and medicinal chemistry continues to expedite the discovery of novel chemotypes with the promise of yielding more efficacious and safer opioid compounds.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37995655/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231124011111&v=2.17.9.post6+86293ac">37995655</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.10.029>10.1016/j.cell.2023.10.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37995655</guid>
<pubDate>Thu, 23 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Tao Che</dc:creator>
<dc:creator>Bryan L Roth</dc:creator>
<dc:date>2023-11-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Molecular basis of opioid receptor signaling</dc:title>
<dc:identifier>pmid:37995655</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.10.029</dc:identifier>
</item>
<item>
<title>Staphylococcus scratches its itch</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37995654/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231124011111&amp;v=2.17.9.post6+86293ac
      <description>Itch exacerbates infection and inflammation-associated skin pathology. In this issue of Cell, Deng et al. identify a V8 protease released by Staphylococcus aureus triggering itch via neuronal protease-activated receptor 1. In so doing, they uncover profound consequences of microbial neurosensory modulation and the ensuing scratch-induced tissue damage that potentiates infection.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Nov 22;186(24):5201-5202. doi: 10.1016/j.cell.2023.10.027.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Itch exacerbates infection and inflammation-associated skin pathology. In this issue of Cell, Deng et al. identify a V8 protease released by Staphylococcus aureus triggering itch via neuronal protease-activated receptor 1. In so doing, they uncover profound consequences of microbial neurosensory modulation and the ensuing scratch-induced tissue damage that potentiates infection.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37995654/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231124011111&v=2.17.9.post6+86293ac">37995654</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.10.027>10.1016/j.cell.2023.10.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37995654</guid>
<pubDate>Thu, 23 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Jack Major</dc:creator>
<dc:creator>Shruti Naik</dc:creator>
<dc:date>2023-11-23</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Staphylococcus scratches its itch</dc:title>
<dc:identifier>pmid:37995654</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.10.027</dc:identifier>
</item>
<item>
<title>Correction to: 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37995350/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231124011111&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 23:ehad613. doi: 10.1093/eurheartj/ehad613. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37995350/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231124011111&v=2.17.9.post6+86293ac">37995350</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad613>10.1093/eurheartj/ehad613</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37995350</guid>
<pubDate>Thu, 23 Nov 2023 06:00:00 -0500</pubDate>
<dc:date>2023-11-23</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC</dc:title>
<dc:identifier>pmid:37995350</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad613</dc:identifier>
</item>
<item>
<title>Stroke and bleeding risk in atrial fibrillation with CHA2DS2-VASC risk score of one: the Norwegian AFNOR study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37995254/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231124011111&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In AF patients at intermediate risk of stroke, OAC use was associated with overall favourable clinical outcomes. Non-anticoagulated AF patients had higher risk of ischaemic stroke compared to the general population without AF with the same risk profile.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 23:ehad659. doi: 10.1093/eurheartj/ehad659. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The benefit of oral anticoagulant (OAC) therapy in atrial fibrillation (AF) and intermediate stroke risk is debated. In a nationwide Norwegian cohort with a non-sex CHA2DS2-VASc risk score of one, this study aimed to investigate (i) stroke and bleeding risk in AF patients with and without OAC treatment, and (ii) the risk of stroke in non-anticoagulated individuals with and without AF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 1 118 762 individuals including 34 460 AF patients were followed during 2011-18 until ischaemic stroke, intracranial haemorrhage, increased CHA2DS2-VASc score, or study end. One-year incidence rates (IRs) were calculated as events per 100 person-years (%/py). Cox regression models provided adjusted hazard ratios (aHRs [95% confidence intervals]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among AF patients, the ischaemic stroke IR was 0.51%/py in OAC users and 1.05%/py in non-users (aHR 0.47 [0.37-0.59]). Intracranial haemorrhage IR was 0.28%/py in OAC users and 0.19%/py in non-users (aHR 1.23 [0.88-1.72]). Oral anticoagulant use was associated with an increased risk of major bleeding (aHR 1.37 [1.16-1.63]) but lower risk of the combined outcome of ischaemic stroke, major bleeding, and mortality (aHR 0.57 [0.51-0.63]). Non-anticoagulated individuals with AF had higher risk of ischaemic stroke compared to non-AF individuals with the same risk profile (aHR 2.47 [2.17-2.81]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In AF patients at intermediate risk of stroke, OAC use was associated with overall favourable clinical outcomes. Non-anticoagulated AF patients had higher risk of ischaemic stroke compared to the general population without AF with the same risk profile.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37995254/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231124011111&v=2.17.9.post6+86293ac">37995254</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad659>10.1093/eurheartj/ehad659</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37995254</guid>
<pubDate>Thu, 23 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Mariam Anjum</dc:creator>
<dc:creator>Inger Ariansen</dc:creator>
<dc:creator>Vidar Hjellvik</dc:creator>
<dc:creator>Randi Selmer</dc:creator>
<dc:creator>Lars J Kjerpeseth</dc:creator>
<dc:creator>Eva Skovlund</dc:creator>
<dc:creator>Marius Myrstad</dc:creator>
<dc:creator>Hanne Ellekjær</dc:creator>
<dc:creator>Ingrid E Christophersen</dc:creator>
<dc:creator>Arnljot Tveit</dc:creator>
<dc:creator>Trygve Berge</dc:creator>
<dc:date>2023-11-23</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Stroke and bleeding risk in atrial fibrillation with CHA2DS2-VASC risk score of one: the Norwegian AFNOR study</dc:title>
<dc:identifier>pmid:37995254</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad659</dc:identifier>
</item>
<item>
<title>Anticoagulation for atrial fibrillation in patients with intermediate stroke risk: is the grey zone becoming less grey?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37995207/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231124011111&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 23:ehad751. doi: 10.1093/eurheartj/ehad751. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37995207/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231124011111&v=2.17.9.post6+86293ac">37995207</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad751>10.1093/eurheartj/ehad751</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37995207</guid>
<pubDate>Thu, 23 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Francis E Marchlinski</dc:creator>
<dc:creator>Alireza Oraii</dc:creator>
<dc:creator>Daniele Muser</dc:creator>
<dc:date>2023-11-23</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Anticoagulation for atrial fibrillation in patients with intermediate stroke risk: is the grey zone becoming less grey?</dc:title>
<dc:identifier>pmid:37995207</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad751</dc:identifier>
</item>
<item>
<title>Comparison of Intravascular Imaging, Functional, or Angiographically Guided Coronary Intervention</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37995152/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231124011111&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Angiography-guided PCI had consistently worse outcomes compared with intravascular imaging-guided and functionally guided PCI. Intravascular imaging-guided PCI was the best strategy to reduce the risk of cardiovascular events.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 5;82(23):2167-2176. doi: 10.1016/j.jacc.2023.09.823. Epub 2023 Oct 23.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In patients undergoing percutaneous coronary intervention (PCI), it remains unclear whether intravascular imaging guidance or functional guidance is the best strategy to optimize outcomes and if the results are different in patients with vs without acute coronary syndromes (ACS).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to evaluate clinical outcomes with imaging-guided PCI or functionally guided PCI when compared with conventional angiography-guided PCI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We searched PUBMED and EMBASE for randomized controlled trials investigating outcomes with intravascular imaging-guided, functionally guided, or angiography-guided PCI. The primary outcome from this network meta-analysis was trial-defined major adverse cardiovascular event (MACE)-a composite of cardiovascular death, myocardial infarction (MI), and target lesion revascularization (TLR). PCI strategies were ranked (best to worst) using P scores.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Our search identified 32 eligible randomized controlled trials and included a total of 22,684 patients. Compared with angiography-guided PCI, intravascular imaging-guided PCI was associated with reduced risk of MACE (relative risk [RR]: 0.72; 95% CI: 0.62-0.82), cardiovascular death (RR: 0.56; 95% CI: 0.42-0.75), MI (RR: 0.81; 95% CI: 0.66-0.99), stent thrombosis (RR: 0.48; 95% CI: 0.31-0.73), and TLR (RR: 0.75; 95% CI: 0.57-0.99). Similarly, when compared with angiography-guided PCI, functionally guided PCI was associated with reduced risk of MACE and MI. Intravascular imaging-guided PCI ranked first for the outcomes of MACE, cardiovascular death, stent thrombosis, and TLR. The results were consistent in the ACS and non-ACS cohorts.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Angiography-guided PCI had consistently worse outcomes compared with intravascular imaging-guided and functionally guided PCI. Intravascular imaging-guided PCI was the best strategy to reduce the risk of cardiovascular events.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37995152/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231124011111&v=2.17.9.post6+86293ac">37995152</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.823>10.1016/j.jacc.2023.09.823</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37995152</guid>
<pubDate>Thu, 23 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Toshiki Kuno</dc:creator>
<dc:creator>Yuko Kiyohara</dc:creator>
<dc:creator>Akiko Maehara</dc:creator>
<dc:creator>Hiroki A Ueyama</dc:creator>
<dc:creator>Polydoros N Kampaktsis</dc:creator>
<dc:creator>Hisato Takagi</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Gary S Mintz</dc:creator>
<dc:creator>Sripal Bangalore</dc:creator>
<dc:date>2023-11-23</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Comparison of Intravascular Imaging, Functional, or Angiographically Guided Coronary Intervention</dc:title>
<dc:identifier>pmid:37995152</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.823</dc:identifier>
</item>
<item>
<title>Frequent Premature Atrial Contractions Lead to Adverse Atrial Remodeling and Atrial Fibrillation in a Swine Model</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37994608/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231124011111&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In this swine model, frequent PACs resulted in adverse atrial structural remodeling with a heightened propensity to AF. PACs originating from the lateral LA produced greater atrial remodeling and longer induced AF duration than the septal-origin PACs. These data provide evidence that frequent PACs can cause adverse atrial remodeling as well as AF, and that the location of ectopic PACs may be clinically meaningful.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 23. doi: 10.1161/CIRCULATIONAHA.123.065874. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Frequent premature atrial complexes (PACs) are associated with future incident atrial fibrillation (AF), but whether PACs contribute to development of AF through adverse atrial remodeling has not been studied. This study aimed to explore the effect of frequent PACs from different sites on atrial remodeling in a swine model.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Forty swine underwent baseline electrophysiologic studies and echocardiography followed by pacemaker implantations and paced PACs (50% burden) at 250-ms coupling intervals for 16 weeks in 4 groups: (1) lateral left atrium (LA) PACs by the coronary sinus (Lat-PAC; n=10), (2) interatrial septal PACs (Sep-PAC; n=10), (3) regular LA pacing at 130 beats/min (Reg-130; n=10), and (4) controls without PACs (n=10). At the final study, repeat studies were performed, followed by tissue histology and molecular analyses focusing on fibrotic pathways.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Lat-PACs were associated with a longer P-wave duration (93.0±9.0 versus 74.2±8.2 and 58.8±7.6 ms; <i>P</i>&lt;0.001) and greater echocardiographic mechanical dyssynchrony (57.5±11.6 versus 35.7±13.0 and 24.4±11.1 ms; <i>P</i>&lt;0.001) compared with Sep-PACs and controls, respectively. After 16 weeks, Lat-PACs led to slower LA conduction velocity (1.1±0.2 versus 1.3±0.2 [Sep-PAC] versus 1.3±0.1 [Reg-130] versus 1.5±0.2 [controls] m/s; <i>P</i>&lt;0.001) without significant change in atrial ERP. The Lat-PAC group had a significantly increased percentage of LA fibrosis and upregulated levels of extracellular matrix proteins (lysyl oxidase and collagen 1 and 8), as well as TGF-β1 (transforming growth factor-β1) signaling proteins (latent and monomer TGF-β1 and phosphorylation/total ratio of SMAD2/3; <i>P</i>&lt;0.05). The Lat-PAC group had the longest inducible AF duration (terminal to baseline: 131 [interquartile range 30, 192] seconds versus 16 [6, 26] seconds [Sep-PAC] versus 22 [11, 64] seconds [Reg-130] versus -1 [-16, 7] seconds [controls]; <i>P</i>&lt;0.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this swine model, frequent PACs resulted in adverse atrial structural remodeling with a heightened propensity to AF. PACs originating from the lateral LA produced greater atrial remodeling and longer induced AF duration than the septal-origin PACs. These data provide evidence that frequent PACs can cause adverse atrial remodeling as well as AF, and that the location of ectopic PACs may be clinically meaningful.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37994608/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231124011111&v=2.17.9.post6+86293ac">37994608</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065874>10.1161/CIRCULATIONAHA.123.065874</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37994608</guid>
<pubDate>Thu, 23 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Satoshi Higuchi</dc:creator>
<dc:creator>Aleksandr Voskoboinik</dc:creator>
<dc:creator>Sung Il Im</dc:creator>
<dc:creator>Adam Lee</dc:creator>
<dc:creator>Jeffrey Olgin</dc:creator>
<dc:creator>Ayla Arbil</dc:creator>
<dc:creator>Junaid Afzal</dc:creator>
<dc:creator>Gregory M Marcus</dc:creator>
<dc:creator>Carol Stillson</dc:creator>
<dc:creator>Dwight Bibby</dc:creator>
<dc:creator>Theodore Abraham</dc:creator>
<dc:creator>Emily Wilson</dc:creator>
<dc:creator>Edward P Gerstenfeld</dc:creator>
<dc:date>2023-11-23</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Frequent Premature Atrial Contractions Lead to Adverse Atrial Remodeling and Atrial Fibrillation in a Swine Model</dc:title>
<dc:identifier>pmid:37994608</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065874</dc:identifier>
</item>
<item>
<title>USP28 Serves as a Key Suppressor of Mitochondrial Morphofunctional Defects and Cardiac Dysfunction in the Diabetic Heart</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37994595/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231124011111&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Our findings provide a USP28-modulated mitochondria homeostasis mechanism that involves the PPARα-Mfn2 axis in diabetic hearts, suggesting that USP28 activation or adeno-associated virus therapy targeting USP28 represents a potential therapeutic strategy for diabetic cardiomyopathy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 23. doi: 10.1161/CIRCULATIONAHA.123.065603. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The majority of people with diabetes are susceptible to cardiac dysfunction and heart failure, and conventional drug therapy cannot correct diabetic cardiomyopathy progression. Herein, we assessed the potential role and therapeutic value of USP28 (ubiquitin-specific protease 28) on the metabolic vulnerability of diabetic cardiomyopathy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The type 2 diabetes mouse model was established using db/db leptin receptor-deficient mice and high-fat diet/streptozotocin-induced mice. Cardiac-specific knockout of USP28 in the db/db background mice was generated by crossbreeding db/m and Myh6-Cre<sup>+</sup>/USP28<sup>fl/fl</sup> mice. Recombinant adeno-associated virus serotype 9 carrying USP28 under cardiac troponin T promoter was injected into db/db mice. High glucose plus palmitic acid-incubated neonatal rat ventricular myocytes and human induced pluripotent stem cell-derived cardiomyocytes were used to imitate diabetic cardiomyopathy in vitro. The molecular mechanism was explored through RNA sequencing, immunoprecipitation and mass spectrometry analysis, protein pull-down, chromatin immunoprecipitation sequencing, and chromatin immunoprecipitation assay.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Microarray profiling of the UPS (ubiquitin-proteasome system) on the basis of db/db mouse hearts and diabetic patients' hearts demonstrated that the diabetic ventricle presented a significant reduction in USP28 expression. Diabetic Myh6-Cre<sup>+</sup>/USP28<sup>fl/fl</sup> mice exhibited more severe progressive cardiac dysfunction, lipid accumulation, and mitochondrial disarrangement, compared with their controls. On the other hand, USP28 overexpression improved systolic and diastolic dysfunction and ameliorated cardiac hypertrophy and fibrosis in the diabetic heart. Adeno-associated virus serotype 9-USP28 diabetic mice also exhibited less lipid storage, reduced reactive oxygen species formation, and mitochondrial impairment in heart tissues than adeno-associated virus serotype 9-null diabetic mice. As a result, USP28 overexpression attenuated cardiac remodeling and dysfunction, lipid accumulation, and mitochondrial impairment in high-fat diet/streptozotocin-induced type 2 diabetes mice. These results were also confirmed in neonatal rat ventricular myocytes and human induced pluripotent stem cell-derived cardiomyocytes. RNA sequencing, immunoprecipitation and mass spectrometry analysis, chromatin immunoprecipitation assays, chromatin immunoprecipitation sequencing, and protein pull-down assay mechanistically revealed that USP28 directly interacted with PPARα (peroxisome proliferator-activated receptor α), deubiquitinating and stabilizing PPARα (Lys152) to promote Mfn2 (mitofusin 2) transcription, thereby impeding mitochondrial morphofunctional defects. However, such cardioprotective benefits of USP28 were largely abrogated in db/db mice with PPARα deletion and conditional loss-of-function of Mfn2.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings provide a USP28-modulated mitochondria homeostasis mechanism that involves the PPARα-Mfn2 axis in diabetic hearts, suggesting that USP28 activation or adeno-associated virus therapy targeting USP28 represents a potential therapeutic strategy for diabetic cardiomyopathy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37994595/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231124011111&v=2.17.9.post6+86293ac">37994595</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065603>10.1161/CIRCULATIONAHA.123.065603</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37994595</guid>
<pubDate>Thu, 23 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Sai-Yang Xie</dc:creator>
<dc:creator>Shi-Qiang Liu</dc:creator>
<dc:creator>Tong Zhang</dc:creator>
<dc:creator>Wen-Ke Shi</dc:creator>
<dc:creator>Yun Xing</dc:creator>
<dc:creator>Wen-Xi Fang</dc:creator>
<dc:creator>Min Zhang</dc:creator>
<dc:creator>Meng-Ya Chen</dc:creator>
<dc:creator>Si-Chi Xu</dc:creator>
<dc:creator>Meng-Qi Fan</dc:creator>
<dc:creator>Lan-Lan Li</dc:creator>
<dc:creator>Heng Zhang</dc:creator>
<dc:creator>Nan Zhao</dc:creator>
<dc:creator>Zhao-Xiang Zeng</dc:creator>
<dc:creator>Si Chen</dc:creator>
<dc:creator>Xiao-Feng Zeng</dc:creator>
<dc:creator>Wei Deng</dc:creator>
<dc:creator>Qi-Zhu Tang</dc:creator>
<dc:date>2023-11-23</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>USP28 Serves as a Key Suppressor of Mitochondrial Morphofunctional Defects and Cardiac Dysfunction in the Diabetic Heart</dc:title>
<dc:identifier>pmid:37994595</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065603</dc:identifier>
</item>
<item>
<title>An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37994553/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231124011111&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: The aspirin-free strategy using low-dose prasugrel compared with the DAPT strategy failed to attest superiority for major bleeding within 1 month after PCI but was noninferior for cardiovascular events within 1 month after PCI. However, the aspirin-free strategy was associated with a signal suggesting an excess of coronary events.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 23. doi: 10.1161/CIRCULATIONAHA.123.066720. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Bleeding rates on dual antiplatelet therapy (DAPT) within 1 month after percutaneous coronary intervention (PCI) remain high in clinical practice, particularly in patients with acute coronary syndrome or high bleeding risk. Aspirin-free strategy might result in lower bleeding early after PCI without increasing cardiovascular events, but its efficacy and safety have not yet been proven in randomized trials.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We randomly assigned 6002 patients with acute coronary syndrome or high bleeding risk just before PCI either to prasugrel (3.75 mg/day) monotherapy or to DAPT with aspirin (81-100 mg/day) and prasugrel (3.75 mg/day) after loading of 20 mg of prasugrel in both groups. The coprimary end points were major bleeding (Bleeding Academic Research Consortium 3 or 5) for superiority and cardiovascular events (a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or stroke) for noninferiority with a relative 50% margin.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The full analysis set population consisted of 5966 patients (no-aspirin group, 2984 patients; DAPT group, 2982 patients; age, 71.6±11.7 years; men, 76.6%; acute coronary syndrome, 75.0%). Within 7 days before randomization, aspirin alone, aspirin with P2Y12 inhibitor, oral anticoagulants, and intravenous heparin infusion were given in 21.3%, 6.4%, 8.9%, and 24.5%, respectively. Adherence to the protocol-specified antiplatelet therapy was 88% in both groups at 1 month. At 1 month, the no-aspirin group was not superior to the DAPT group for the coprimary bleeding end point (4.47% and 4.71%; hazard ratio, 0.95 [95% CI, 0.75-1.20]; <i>P</i><sub>superiority</sub>=0.66). The no-aspirin group was noninferior to the DAPT group for the coprimary cardiovascular end point (4.12% and 3.69%; hazard ratio, 1.12 [95% CI, 0.87-1.45]; <i>P</i><sub>non</sub><sub>inferiority</sub>=0.01). There was no difference in net adverse clinical outcomes and each component of coprimary cardiovascular end point. There was an excess of any unplanned coronary revascularization (1.05% and 0.57%; hazard ratio, 1.83 [95%CI, 1.01-3.30]) and subacute definite or probable stent thrombosis (0.58% and 0.17%; hazard ratio, 3.40 [95% CI, 1.26-9.23]) in the no-aspirin group compared with the DAPT group.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The aspirin-free strategy using low-dose prasugrel compared with the DAPT strategy failed to attest superiority for major bleeding within 1 month after PCI but was noninferior for cardiovascular events within 1 month after PCI. However, the aspirin-free strategy was associated with a signal suggesting an excess of coronary events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04609111.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37994553/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231124011111&v=2.17.9.post6+86293ac">37994553</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066720>10.1161/CIRCULATIONAHA.123.066720</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37994553</guid>
<pubDate>Thu, 23 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Masahiro Natsuaki</dc:creator>
<dc:creator>Hirotoshi Watanabe</dc:creator>
<dc:creator>Takeshi Morimoto</dc:creator>
<dc:creator>Ko Yamamoto</dc:creator>
<dc:creator>Yuki Obayashi</dc:creator>
<dc:creator>Ryusuke Nishikawa</dc:creator>
<dc:creator>Kenji Ando</dc:creator>
<dc:creator>Takenori Domei</dc:creator>
<dc:creator>Satoru Suwa</dc:creator>
<dc:creator>Manabu Ogita</dc:creator>
<dc:creator>Tsuyoshi Isawa</dc:creator>
<dc:creator>Hiroyuki Takenaka</dc:creator>
<dc:creator>Takashi Yamamoto</dc:creator>
<dc:creator>Tetsuya Ishikawa</dc:creator>
<dc:creator>Itaru Hisauchi</dc:creator>
<dc:creator>Kohei Wakabayashi</dc:creator>
<dc:creator>Yuko Onishi</dc:creator>
<dc:creator>Kiyoshi Hibi</dc:creator>
<dc:creator>Kazuya Kawai</dc:creator>
<dc:creator>Ruka Yoshida</dc:creator>
<dc:creator>Hiroshi Suzuki</dc:creator>
<dc:creator>Gaku Nakazawa</dc:creator>
<dc:creator>Takanori Kusuyama</dc:creator>
<dc:creator>Itsuro Morishima</dc:creator>
<dc:creator>Koh Ono</dc:creator>
<dc:creator>Takeshi Kimura</dc:creator>
<dc:date>2023-11-23</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial</dc:title>
<dc:identifier>pmid:37994553</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066720</dc:identifier>
</item>
<item>
<title>Reply: Potential Mechanisms of Troponin Release in Stable Coronary Artery Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37993208/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231124011111&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 28;82(22):e217. doi: 10.1016/j.jacc.2023.09.816.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37993208/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231124011111&v=2.17.9.post6+86293ac">37993208</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.816>10.1016/j.jacc.2023.09.816</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37993208</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Ryan Wereski</dc:creator>
<dc:creator>Andrew R Chapman</dc:creator>
<dc:creator>Nicholas L Mills</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Potential Mechanisms of Troponin Release in Stable Coronary Artery Disease</dc:title>
<dc:identifier>pmid:37993208</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.816</dc:identifier>
</item>
<item>
<title>Potential Mechanisms of Troponin Release in Stable Coronary Artery Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37993207/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231124011111&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 28;82(22):e215. doi: 10.1016/j.jacc.2023.08.060.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37993207/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231124011111&v=2.17.9.post6+86293ac">37993207</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.060>10.1016/j.jacc.2023.08.060</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37993207</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Ramdas G Pai</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Potential Mechanisms of Troponin Release in Stable Coronary Artery Disease</dc:title>
<dc:identifier>pmid:37993207</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.060</dc:identifier>
</item>
<item>
<title>Primary Prevention of Subclinical Atherosclerosis in Young Adults: JACC Review Topic of the Week</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37993206/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231124011111&amp;v=2.17.9.post6+86293ac
      <description>There is growing evidence that the atherosclerotic process that leads to symptomatic cardiovascular disease (CVD) starts at an early age. In young adults, exposure to low-density lipoprotein-cholesterol and other cardiovascular risk factor (CVRF) mediators, even at levels considered within normal limits, increases the prevalence of subclinical atherosclerosis and is associated with greater risk of cardiovascular events later in life. The optimal CVRF targets to prevent CVD in asymptomatic young...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 28;82(22):2152-2162. doi: 10.1016/j.jacc.2023.09.817.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">There is growing evidence that the atherosclerotic process that leads to symptomatic cardiovascular disease (CVD) starts at an early age. In young adults, exposure to low-density lipoprotein-cholesterol and other cardiovascular risk factor (CVRF) mediators, even at levels considered within normal limits, increases the prevalence of subclinical atherosclerosis and is associated with greater risk of cardiovascular events later in life. The optimal CVRF targets to prevent CVD in asymptomatic young individuals (&lt;40 years) are unknown. The randomized controlled PRECAD (Prevent Coronary Artery Disease) trial has been developed to assess the potential benefit of an aggressive control of CVRF in otherwise healthy young adults. The hypothesis of PRECAD is that in subjects aged 20 to 39 years without known CVD, maintaining low-density lipoprotein-cholesterol &lt;70 mg/dL and strict control of blood pressure and glucose will prevent the onset of atherosclerosis and/or its progression. The primary endpoint will be the change in total atherosclerosis burden, a surrogate for CVD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37993206/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231124011111&v=2.17.9.post6+86293ac">37993206</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.817>10.1016/j.jacc.2023.09.817</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37993206</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Ana Devesa</dc:creator>
<dc:creator>Borja Ibanez</dc:creator>
<dc:creator>Waqas A Malick</dc:creator>
<dc:creator>Elizabeth O Tinuoye</dc:creator>
<dc:creator>Jessica Bustamante</dc:creator>
<dc:creator>Carlos Peyra</dc:creator>
<dc:creator>Robert S Rosenson</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Valentin Fuster</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Primary Prevention of Subclinical Atherosclerosis in Young Adults: JACC Review Topic of the Week</dc:title>
<dc:identifier>pmid:37993206</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.817</dc:identifier>
</item>
<item>
<title>Novel Imaging Approaches to Cardiac Manifestations of Systemic Inflammatory Diseases: JACC Scientific Statement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37993205/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231124011111&amp;v=2.17.9.post6+86293ac
      <description>Derangements in the innate and adaptive immune responses observed in systemic inflammatory syndromes contributes to unique elevated atherosclerotic risk and incident cardiovascular disease. Novel multimodality imaging techniques may improve diagnostic precision for the screening and monitoring of disease activity. The integrated application of these technologies lead to earlier diagnosis and noninvasive monitoring of cardiac involvement in systemic inflammatory diseases that will aid in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 28;82(22):2128-2151. doi: 10.1016/j.jacc.2023.09.819.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Derangements in the innate and adaptive immune responses observed in systemic inflammatory syndromes contributes to unique elevated atherosclerotic risk and incident cardiovascular disease. Novel multimodality imaging techniques may improve diagnostic precision for the screening and monitoring of disease activity. The integrated application of these technologies lead to earlier diagnosis and noninvasive monitoring of cardiac involvement in systemic inflammatory diseases that will aid in preclinical studies, enhance patient selection, and provide surrogate endpoints in clinical trials, thereby improving clinical outcomes. We review the common cardiovascular manifestations of immune-mediated systemic inflammatory diseases and address the clinical and investigational role of advanced multimodality cardiac imaging.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37993205/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231124011111&v=2.17.9.post6+86293ac">37993205</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.819>10.1016/j.jacc.2023.09.819</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37993205</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Brittany N Weber</dc:creator>
<dc:creator>Julie J Paik</dc:creator>
<dc:creator>Ayaz Aghayev</dc:creator>
<dc:creator>Allan L Klein</dc:creator>
<dc:creator>Sophie I Mavrogeni</dc:creator>
<dc:creator>Paul B Yu</dc:creator>
<dc:creator>Monica Mukherjee</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Novel Imaging Approaches to Cardiac Manifestations of Systemic Inflammatory Diseases: JACC Scientific Statement</dc:title>
<dc:identifier>pmid:37993205</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.819</dc:identifier>
</item>
<item>
<title>Learning From Machines to Predict Mortality After Surgical or Percutaneous Revascularization</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37993204/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231124011111&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 28;82(22):2125-2127. doi: 10.1016/j.jacc.2023.10.002.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37993204/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231124011111&v=2.17.9.post6+86293ac">37993204</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.002>10.1016/j.jacc.2023.10.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37993204</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Paul A Kurlansky</dc:creator>
<dc:creator>John A Bittl</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Learning From Machines to Predict Mortality After Surgical or Percutaneous Revascularization</dc:title>
<dc:identifier>pmid:37993204</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.002</dc:identifier>
</item>
<item>
<title>Can Machine Learning Aid the Selection of Percutaneous vs Surgical Revascularization?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37993203/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231124011111&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: An ML-based approach for identifying individuals who benefit from CABG or PCI is feasible and effective. Implementation of this model in health care systems-trained to collect large numbers of parameters-may harmonize decision making globally. (Synergy Between PCI With TAXUS and Cardiac Surgery: SYNTAX Extended Survival [SYNTAXES]; NCT03417050; SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries; NCT00114972).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 28;82(22):2113-2124. doi: 10.1016/j.jacc.2023.09.818.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In patients with 3-vessel coronary artery disease (CAD) and/or left main CAD, individual risk prediction plays a key role in deciding between percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The aim of this study was to assess whether these individualized revascularization decisions can be improved by applying machine learning (ML) algorithms and integrating clinical, biological, and anatomical factors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In the SYNTAX (Synergy between PCI with Taxus and Cardiac Surgery) study, ML algorithms (Lasso regression, gradient boosting) were used to develop a prognostic index for 5-year death, which was combined, in the second stage, with assigned treatment (PCI or CABG) and prespecified effect-modifiers: disease type (3-vessel or left main CAD) and anatomical SYNTAX score. The model's discriminative ability to predict the risk of 5-year death and treatment benefit between PCI and CABG was cross-validated in the SYNTAX trial (n = 1,800) and externally validated in the CREDO-Kyoto (Coronary REvascularization Demonstrating Outcome Study in Kyoto) registry (n = 7,362), and then compared with the original SYNTAX score II 2020 (SSII-2020).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The hybrid gradient boosting model performed best for predicting 5-year all-cause death with C-indexes of 0.78 (95% CI: 0.75-0.81) in cross-validation and 0.77 (95% CI: 0.76-0.79) in external validation. The ML models discriminated 5-year mortality better than the SSII-2020 in the external validation cohort and identified heterogeneity in the treatment benefit of CABG vs PCI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: An ML-based approach for identifying individuals who benefit from CABG or PCI is feasible and effective. Implementation of this model in health care systems-trained to collect large numbers of parameters-may harmonize decision making globally. (Synergy Between PCI With TAXUS and Cardiac Surgery: SYNTAX Extended Survival [SYNTAXES]; NCT03417050; SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries; NCT00114972).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37993203/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231124011111&v=2.17.9.post6+86293ac">37993203</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.818>10.1016/j.jacc.2023.09.818</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37993203</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Kai Ninomiya</dc:creator>
<dc:creator>Shigetaka Kageyama</dc:creator>
<dc:creator>Hiroki Shiomi</dc:creator>
<dc:creator>Nozomi Kotoku</dc:creator>
<dc:creator>Shinichiro Masuda</dc:creator>
<dc:creator>Pruthvi C Revaiah</dc:creator>
<dc:creator>Scot Garg</dc:creator>
<dc:creator>Neil O'Leary</dc:creator>
<dc:creator>David van Klaveren</dc:creator>
<dc:creator>Takeshi Kimura</dc:creator>
<dc:creator>Yoshinobu Onuma</dc:creator>
<dc:creator>Patrick W Serruys</dc:creator>
<dc:creator>SYNTAX Investigators</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Can Machine Learning Aid the Selection of Percutaneous vs Surgical Revascularization?</dc:title>
<dc:identifier>pmid:37993203</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.818</dc:identifier>
</item>
<item>
<title>Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure: STEPping Across the Ejection Fraction Divide</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37993202/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231124011111&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 28;82(22):2097-2100. doi: 10.1016/j.jacc.2023.09.812. Epub 2023 Oct 8.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37993202/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231124011111&v=2.17.9.post6+86293ac">37993202</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.812>10.1016/j.jacc.2023.09.812</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37993202</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>John W Ostrominski</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure: STEPping Across the Ejection Fraction Divide</dc:title>
<dc:identifier>pmid:37993202</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.812</dc:identifier>
</item>
<item>
<title>Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37993201/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231124011111&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In patients with HFpEF and obesity, semaglutide 2.4 mg improved symptoms, physical limitations, and exercise function, and reduced inflammation and body weight to a similar extent across LVEF categories. These data support treatment with semaglutide in patients with the obesity phenotype of HFpEF regardless of LVEF. (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity [STEP-HFpEF]; NCT04788511).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 28;82(22):2087-2096. doi: 10.1016/j.jacc.2023.09.811. Epub 2023 Oct 8.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Many therapies for heart failure (HF) have shown differential impact across the spectrum of left ventricular ejection fraction (LVEF).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: In this prespecified analysis, the authors assessed the effects of semaglutide across the baseline LVEF strata in patients with the obesity phenotype of HF with preserved ejection fraction (HFpEF) in the STEP-HFpEF (Semaglutide Treatment Effect in People with obesity and HFpEF) trial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: STEP-HFpEF randomized 529 patients (263 semaglutide; 266 placebo). For this prespecified analysis, patients were categorized into 3 groups based on LVEF: 45% to 49% (n = 85), 50% to 59% (n = 215), and ≥60% (n = 229).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At 52 weeks, semaglutide improved the dual primary endpoints of Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (estimated treatment difference: EF [ejection fraction] 45%-49%: 5.0 points [95% CI: -2.7 to 12.8 points], EF 50%-59%: 9.8 points [95% CI: 5.0 to 14.6 points], and EF ≥60%: 7.4 points [95% CI: 2.8 to 12.0 points]; P interaction = 0.56) and body weight (EF: 45%-49%: -7.6 [95% CI: -10.7 to -4.4], EF 50%-59%: -10.6 [95% CI: -12.6 to -8.6] and EF ≥60%: -11.9 [95% CI: -13.8 to -9.9]; P interaction = 0.08), to a similar extent across LVEF categories. Likewise, LVEF did not influence the benefit of semaglutide on confirmatory secondary endpoints: 6-minute walk distance (P interaction = 0.19), hierarchal composite endpoint (P interaction = 0.43), and high-sensitivity C-reactive protein (P interaction = 0.26); or exploratory endpoint of N-terminal pro-brain natriuretic peptide (P interaction = 0.96). Semaglutide was well-tolerated across LVEF categories.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with HFpEF and obesity, semaglutide 2.4 mg improved symptoms, physical limitations, and exercise function, and reduced inflammation and body weight to a similar extent across LVEF categories. These data support treatment with semaglutide in patients with the obesity phenotype of HFpEF regardless of LVEF. (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity [STEP-HFpEF]; NCT04788511).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37993201/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231124011111&v=2.17.9.post6+86293ac">37993201</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.811>10.1016/j.jacc.2023.09.811</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37993201</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Steen Z Abildstrøm</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:creator>Melanie J Davies</dc:creator>
<dc:creator>Dalane W Kitzman</dc:creator>
<dc:creator>Mark C Petrie</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Subodh Verma</dc:creator>
<dc:creator>Walter P Abhayaratna</dc:creator>
<dc:creator>Vijay Chopra</dc:creator>
<dc:creator>Justin A Ezekowitz</dc:creator>
<dc:creator>Michael Fu</dc:creator>
<dc:creator>Hiroshi Ito</dc:creator>
<dc:creator>Małgorzata Lelonek</dc:creator>
<dc:creator>Julio Núñez</dc:creator>
<dc:creator>Eduardo Perna</dc:creator>
<dc:creator>Morten Schou</dc:creator>
<dc:creator>Michele Senni</dc:creator>
<dc:creator>Peter van der Meer</dc:creator>
<dc:creator>Dirk von Lewinski</dc:creator>
<dc:creator>Dennis Wolf</dc:creator>
<dc:creator>Rebecca L Altschul</dc:creator>
<dc:creator>Søren Rasmussen</dc:creator>
<dc:creator>Mikhail N Kosiborod</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction</dc:title>
<dc:identifier>pmid:37993201</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.811</dc:identifier>
</item>
<item>
<title>Charting a Course for Atherosclerosis Regression: Shifting the Paradigm</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37993200/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231124011111&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Nov 28;82(22):2084-2086. doi: 10.1016/j.jacc.2023.10.003.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37993200/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231124011111&v=2.17.9.post6+86293ac">37993200</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.003>10.1016/j.jacc.2023.10.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37993200</guid>
<pubDate>Wed, 22 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Charles A German</dc:creator>
<dc:creator>Michael D Shapiro</dc:creator>
<dc:date>2023-11-22</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Charting a Course for Atherosclerosis Regression: Shifting the Paradigm</dc:title>
<dc:identifier>pmid:37993200</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.003</dc:identifier>
</item>





























</channel>
</rss>